Bempikibart
Monoclonal antibody
Also known as ADX-914
Evidence outlook
Mid-stage readout reported
A Phase 2 readout has been reported. The trial rows below carry the recorded result.
Latest reported trial: SIGNAL-AD (NCT05509023) · Phase 2 · missed primary endpoint · grade pending
Also in development:Alopecia Areata · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SIGNAL-AD NCT05509023 · Atopic Dermatitis Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Registry: NCT05509023 | 2 | Part A only: Safety parameters including incidence of serious adverse events and adverse events of special interest (14 Weeks); Part A and B: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 14 for ADX-914 vs placebo (14 Weeks) 2024-12 | Part B primary endpoint, mean percent change in EASI from baseline to week 14: bempikibart 200 mg Q2W 74% vs placebo 76%; not statistically significant (Q32 Bio, 2024-12-10). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Alopecia Areata: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bempikibart: this drug | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | Partial signal | NCT06018428: Part A primary, mean relative percent change in SALT score at week 24 vs placebo: the planned primary analysis was not performed after one site was excluded for protocol violations, so no primary-analysis result exists. Post-hoc per-protocol analysis (SALT 50-100): bempikibart (n=23) 16% mean reduction vs placebo (n=4) 2% reduction; Wilcoxon rank sum p=0.045. Part B is single-arm and has no comparison. | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | NCT05051761: Primary endpoint, SALT score <=20 at week 24: both jaktinib doses superior to placebo (p<0.0001) (2024-06-13). | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Rezpegaldesleukin | Phase 2 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent